Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells $599,499.90 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CFO Eric Bjerkholt sold 6,001 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $99.90, for a total value of $599,499.90. Following the transaction, the chief financial officer directly owned 36,355 shares in the company, valued at approximately $3,631,864.50. The trade was a 14.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Bjerkholt also recently made the following trade(s):

• On Monday, July 6th, Eric Bjerkholt sold 5,000 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $122.25, for a total value of $611,250.00.
• On Monday, June 8th, Eric Bjerkholt sold 5,000 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $93.82, for a total value of $469,100.00.

Mirum Pharmaceuticals Stock Up 1.9%

Shares of NASDAQ:MIRM opened at $100.64 on Friday. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 2.74. The firm has a market capitalization of $6.53 billion, a PE ratio of -6.92 and a beta of 0.52. The firm’s 50-day moving average is $110.91 and its two-hundred day moving average is $101.99. Mirum Pharmaceuticals, Inc. has a 1 year low of $63.23 and a 1 year high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). The business had revenue of $176.24 million during the quarter, compared to analysts’ expectations of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The company’s revenue for the quarter was up 37.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.12) EPS. Analysts predict that Mirum Pharmaceuticals, Inc. will post -1.31 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Robert W. Baird set a $123.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, August 6th. HC Wainwright cut their price objective on Mirum Pharmaceuticals from $185.00 to $140.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Citizens Jmp reduced their price objective on Mirum Pharmaceuticals from $146.00 to $137.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 6th. Wall Street Zen upgraded Mirum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, TD Cowen lowered their target price on Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Mirum Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $137.33.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in MIRM. ABS Investment Management LLC purchased a new position in Mirum Pharmaceuticals in the second quarter valued at approximately $245,847,000. Quantbot Technologies LP purchased a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter worth approximately $44,000. Cullen Frost Bankers Inc. purchased a new stake in shares of Mirum Pharmaceuticals during the 4th quarter worth approximately $30,000. Eurizon Capital SGR S.p.A. acquired a new position in shares of Mirum Pharmaceuticals in the 4th quarter valued at $32,000. Finally, CIBC Private Wealth Group LLC acquired a new position in shares of Mirum Pharmaceuticals in the 4th quarter valued at $32,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.